Vivus/KV EvaMist approval
This article was originally published in Pharmaceutical Approvals Monthly
FDA approves Vivus' metered-dose topical estradiol spray EvaMist to treat moderate to severe vasomotor symptoms due to menopause. The July 27 approval triggers a $140 million payment to Vivus from KV Pharmaceutical, which will market the drug with its more than 280-strong sales force. Vivus received a $10 million up-front payment and is eligible to get more money based on sales milestones. The firm is touting EvaMist's safety profile, but will be competing in a crowded transdermal estradiol market with close competitors Esprit Pharma's Estrasorb, Ascend's EstroGel and BioSante's Elestrin. Vivus is also developing an obesity combo agent, Qnexa (1Pharmaceutical Approvals Monthly September 2006, p. 11)...
You may also be interested in...
While Vivus is getting ready to submit its NDA for Evamist early in the fourth quarter of 2006, the company is calling its obesity drug Qnexa a potential blockbuster and earmarking it as its top priority.
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
The recently US FDA-cleared Velys robotic-assisted system from DePuy Synthes has distinct features. It also has a small footprint that makes it well-suited for ambulatory surgery centers. See what Larry Biegelsen, an analyst with Wells Fargo, said about it here.